相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。LRRK2 in Parkinson disease: challenges of clinical trials
Eduardo Tolosa et al.
NATURE REVIEWS NEUROLOGY (2020)
CSF and blood biomarkers for Parkinson's disease
Lucilla Parnetti et al.
LANCET NEUROLOGY (2019)
Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease
Michael X. Henderson et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, alpha-synuclein, amyloid-beta and insulin resistance in neurodegenerative diseases
I. A. Clark et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
Inger van Steenoven et al.
MOVEMENT DISORDERS (2018)
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease
Shuchi Mittal et al.
SCIENCE (2017)
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease
Nour K. Majbour et al.
MOLECULAR NEURODEGENERATION (2016)
Increased Peripheral Inflammation in Asymptomatic Leucine-Rich Repeat Kinase 2 Mutation Carriers
Nicolas Dzamko et al.
MOVEMENT DISORDERS (2016)
Cerebrospinal Fluid Biomarkers and Clinical Features in Leucine-Rich Repeat Kinase 2 (LRRK2) Mutation Carriers
Dolores Vilas et al.
MOVEMENT DISORDERS (2016)
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
Nour K. Majbour et al.
MOVEMENT DISORDERS (2016)
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
Nishant N. Vaikath et al.
NEUROBIOLOGY OF DISEASE (2015)
INFLAMMATION IS GENETICALLY IMPLICATED IN PARKINSON'S DISEASE
N. Dzamko et al.
NEUROSCIENCE (2015)
Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease
Lorraine V. Kalia et al.
JAMA NEUROLOGY (2015)
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity
Tessandra Stewart et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration
Carolina Cebrian et al.
NATURE COMMUNICATIONS (2014)
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
Jan O. Aasly et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Genetic Variants of LRRK2 in Taiwanese Parkinson's Disease
Yih-Ru Wu et al.
PLOS ONE (2013)
An emerging role for LRRK2 in the immune system
Nicolas Dzamko et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Mark S. Moehle et al.
JOURNAL OF NEUROSCIENCE (2012)
The neuropathology of genetic Parkinson's disease
Markos Poulopoulos et al.
MOVEMENT DISORDERS (2012)
Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naive Patients with Parkinson's Disease
Min Jeong Park et al.
JOURNAL OF CLINICAL NEUROLOGY (2011)
Subclinical signs in LRRK2 mutation carriers
Krisztina K. Johansen et al.
PARKINSONISM & RELATED DISORDERS (2011)
Novel Pathogenic LRRK2 p.Asn1437His Substitution in Familial Parkinson's Disease
Jan O. Aasly et al.
MOVEMENT DISORDERS (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
Genealogical studies in LRRK2-associated Parkinson's disease in central Norway
Krisztina K. Johansen et al.
PARKINSONISM & RELATED DISORDERS (2010)
Cerebrospinal Tau, Phospho-Tau, and Beta-Amyloid and Neuropsychological Functions in Parkinson's Disease
Yaroslau Compta et al.
MOVEMENT DISORDERS (2009)
Parkinson's disease: a dual-hit hypothesis
C. H. Hawkes et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)
Neuroinflammation in the pathophysiology of Parkinson's disease:: Evidence from animal models to human in vivo studies with [11C]-PKI1195 PET
Anna L. Bartels et al.
MOVEMENT DISORDERS (2007)
Clinical features of LRRK2-associated Parkinson's disease in Central Norway
JO Aasly et al.
ANNALS OF NEUROLOGY (2005)
Genetic ablation of tumor necrosis factor-alpha (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum
B Ferger et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Ageing, tumour necrosis factor-alpha (TNF-α) and atherosclerosis
H Bruunsgaard et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
分享论文
